Quantcast
Last updated on April 16, 2014 at 7:25 EDT

Latest CC chemokine receptors Stories

How Do Tumor Cells Create Their Own Pathways
2012-07-10 15:34:19

Potential new treatment for metastatic colon cancer How does a tumor cell set up a signaling pathway in order to metastasize? Scientists at Technische Universität München's (TUM) Klinikum rechts der Isar and Helmholtz Zentrum München have made a significant discovery in this area by studying colon cancer. They have learned that the tumor cells release certain proteins known as chemokines. In the case of metastatic colon cancer cells, the...

2011-01-26 07:30:00

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23. This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK)...

2010-09-21 06:30:00

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials. These...

2010-06-17 05:00:00

MOUNTAIN VIEW, Calif., June 17 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA). Data demonstrating that CCX354 was safe and well tolerated with a clear...

2010-03-22 07:30:00

MOUNTAIN VIEW, Calif., March 22 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2. This receptor has been shown to play a role in the inflammatory response associated with metabolic diseases including type 2 diabetes, as well as other diseases including vascular restenosis following stent placement, and...

2009-07-08 17:39:00

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time. "It...